Arcus Biosciences develops and advances oncology therapies, including Etrumadenant (A2a/A2b antagonist), Zimberelimab (anti-PD-1 antibody), Domvanalimab (anti-TIGIT antibody), Quemliclustat (CD73 ...
The president of Arcus Biosciences sold 68,569 shares for $2.0 million during the July 9 and July 10 trading sessions. All shares in this filing were held indirectly by a trust, with the insider ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
82,997 shares were sold indirectly on Dec. 4, 2025, for a transaction value of ~$2.1 million based on a weighted average sale price of $24.71 per share. The sale represented 5.91% of total holdings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results